Literature DB >> 17764056

Pulmonary function tests in connective tissue disease.

Athol U Wells1.   

Abstract

The interpretation of pulmonary function tests (PFTs) in patients with connective tissue disease poses considerable difficulties in clinical practice. In established lung disease, several characteristic PFT profiles are recognized for individual complications, including pulmonary fibrosis, pulmonary vascular disease, extrapulmonary restriction, and intrinsic airway disease. PFTs play a central role in the investigation of respiratory symptoms and are sensitive in the detection of interstitial lung disease and pulmonary vascular disease. The staging of disease severity using PFTs is an invaluable guide to prognosis. Maximal exercise testing has an ancillary role in selected patients and is most often useful in demonstrating that limited disease is not clinically significant. The interpretation of PFTs is most difficult when, as is commonly the case, two or more pulmonary complications coexist, each having separate functional effects. Finally, the use of PFTs in routine monitoring is discussed.

Entities:  

Mesh:

Year:  2007        PMID: 17764056     DOI: 10.1055/s-2007-985610

Source DB:  PubMed          Journal:  Semin Respir Crit Care Med        ISSN: 1069-3424            Impact factor:   3.119


  14 in total

1.  Interstitial lung disease in classic and skin-predominant dermatomyositis: a retrospective study with screening recommendations.

Authors:  Pamela A Morganroth; Mary Elizabeth Kreider; Joyce Okawa; Lynne Taylor; Victoria P Werth
Journal:  Arch Dermatol       Date:  2010-07

2.  Quantitative computerized two-point correlation analysis of lung CT scans correlates with pulmonary function in pulmonary sarcoidosis.

Authors:  Barbaros Selnur Erdal; Elliott D Crouser; Vedat Yildiz; Mark A King; Andrew T Patterson; Michael V Knopp; Bradley D Clymer
Journal:  Chest       Date:  2012-12       Impact factor: 9.410

Review 3.  Treatment of Systemic Sclerosis-related Interstitial Lung Disease: A Review of Existing and Emerging Therapies.

Authors:  Elizabeth R Volkmann; Donald P Tashkin
Journal:  Ann Am Thorac Soc       Date:  2016-11

4.  Evaluation of rheumatoid arthritis and connective tissue disease-related interstitial lung disease with pulmonary physiologic test, HRCT, and patient-based measures of dyspnea and functional disability.

Authors:  Atakan Topcu; H Hakan Mursaloglu; Yasemin Yalcinkaya; Sait Karakurt; Burcu Yagiz; Zeynep Alaca; Meryem Demir; Belkis Nihan Coskun; Ediz Dalkilic; Nevsun Inanc
Journal:  Clin Rheumatol       Date:  2021-04-03       Impact factor: 2.980

Review 5.  Interstitial lung disease in connective tissue disease--mechanisms and management.

Authors:  Athol U Wells; Christopher P Denton
Journal:  Nat Rev Rheumatol       Date:  2014-09-30       Impact factor: 20.543

6.  Effect of Test Interface on Respiratory Muscle Activity and Pulmonary Function During Respiratory Testing in Healthy Adults: A Pilot Study.

Authors:  Elaheh Sajjadi; Patrick C Mabe; Yasin B Seven; Barbara K Smith
Journal:  Cardiopulm Phys Ther J       Date:  2022-04

7.  Connective Tissue Disease-associated Interstitial Lung Disease: A review.

Authors:  Markus Gutsche; Glenn D Rosen; Jeffrey J Swigris
Journal:  Curr Respir Care Rep       Date:  2012-09-21

8.  Lung volumes and airway resistance in patients with a possible restrictive pattern on spirometry.

Authors:  Kenia Schultz; Luiz Carlos D'Aquino; Maria Raquel Soares; Andrea Gimenez; Carlos Alberto de Castro Pereira
Journal:  J Bras Pneumol       Date:  2016 Sep-Oct       Impact factor: 2.624

9.  Serum KL-6 levels reflect the severity of interstitial lung disease associated with connective tissue disease.

Authors:  Jeong Seok Lee; Eun Young Lee; You-Jung Ha; Eun Ha Kang; Yun Jong Lee; Yeong Wook Song
Journal:  Arthritis Res Ther       Date:  2019-02-14       Impact factor: 5.156

Review 10.  Molecular biomarkers in interstitial lung diseases.

Authors:  Angelo De Lauretis; Elisabetta A Renzoni
Journal:  Mol Diagn Ther       Date:  2014-10       Impact factor: 4.074

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.